Scholarlink

Background <p>The hypothesis of immune and inflammatory dysregulation has been supported in the pathogenesis of schizophrenia; this systematic review and meta-analysis aims to evaluate the efficacy and safety of celecoxib, which is a COX-2 inhibitor with anti-inflammatory effects, in the management of schizophrenia.</p> Methods <p>A comprehensive search of electronic databases, including PubMed, Scopus, Cochrane, and Web of Science, was performed in February 2025. We included only randomized controlled trials (RCTs) comparing celecoxib alone or as an adjunct to antipsychotics to placebo. Risk of bias was assessed using the ROB-2 tool, and the data of included studies were extracted and analyzed using RevMan 5.4 software. The primary outcome was the change in PANSS (Positive and Negative Syndrome Scale) total score.</p> Results <p>Seven RCT studies comprising 438 patients with schizophrenia were included in this study. The risk of bias was low in most of the included studies. Celecoxib showed statistically significant improvement in PANSS total score (MD = −&#xa0;8.45, 95% CI [−&#xa0;13.62, -3.28], <i>p</i> value = 0.001), PANSS-positive scale (MD = −&#xa0;3.34, 95% CI [−&#xa0;4.67, −&#xa0;2.02], <i>P</i> &lt; 0.00001), PANSS-negative sub-scales (MD = −&#xa0;2.47, 95% CI [−&#xa0;3.75, −&#xa0;1.19], <i>P</i> = 0.00002), and general psychopathology (MD = −&#xa0;4.47, 95% CI [8.10, −&#xa0;0.85], <i>P</i> = 0.02). No publication bias was detected based on the DOI plot.</p> Conclusion <p>This study’s findings provide insights into the potential anti-inflammatory benefits of celecoxib in schizophrenia treatment. However, study limitations warrant cautious interpretation, highlighting the need for larger, well-designed trials to identify patient subgroups that may benefit most from this approach.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月20日

查看全文
  • NourAllah Farag,
  • Abdullah Selim,
  • Osama Hassan,
  • Hamdy A. Makhlouf,
  • Mahmoud Soliman,
  • Lamees Taman,
  • Omar Kassar

摘要

Background

The hypothesis of immune and inflammatory dysregulation has been supported in the pathogenesis of schizophrenia; this systematic review and meta-analysis aims to evaluate the efficacy and safety of celecoxib, which is a COX-2 inhibitor with anti-inflammatory effects, in the management of schizophrenia.

Methods

A comprehensive search of electronic databases, including PubMed, Scopus, Cochrane, and Web of Science, was performed in February 2025. We included only randomized controlled trials (RCTs) comparing celecoxib alone or as an adjunct to antipsychotics to placebo. Risk of bias was assessed using the ROB-2 tool, and the data of included studies were extracted and analyzed using RevMan 5.4 software. The primary outcome was the change in PANSS (Positive and Negative Syndrome Scale) total score.

Results

Seven RCT studies comprising 438 patients with schizophrenia were included in this study. The risk of bias was low in most of the included studies. Celecoxib showed statistically significant improvement in PANSS total score (MD = − 8.45, 95% CI [− 13.62, -3.28], p value = 0.001), PANSS-positive scale (MD = − 3.34, 95% CI [− 4.67, − 2.02], P < 0.00001), PANSS-negative sub-scales (MD = − 2.47, 95% CI [− 3.75, − 1.19], P = 0.00002), and general psychopathology (MD = − 4.47, 95% CI [8.10, − 0.85], P = 0.02). No publication bias was detected based on the DOI plot.

Conclusion

This study’s findings provide insights into the potential anti-inflammatory benefits of celecoxib in schizophrenia treatment. However, study limitations warrant cautious interpretation, highlighting the need for larger, well-designed trials to identify patient subgroups that may benefit most from this approach.